Φορτώνει......
Spironolactone Use in Heart Failure Patients With End‐Stage Renal Disease on Hemodialysis: Is It Safe?
BACKGROUND: Spironolactone is used in the treatment of cardiovascular disease, but is contraindicated in renal dysfunction due to the risk of hyperkalemia. It is not known if patients with end‐stage renal disease (ESRD) on hemodialysis are at the same risk for hyperkalemia. The objective of this stu...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Cardiol |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Wiley Periodicals, Inc.
2010
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6653125/ https://ncbi.nlm.nih.gov/pubmed/20960534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.20838 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|